Periodicidad semestral: flujo continuo.
ISSN - Electrónico: 2661-6947 / DOI: 10.36015 • LILACS BIREME (19784); LATINDEX (20666)
INTRODUCTION. Ovarian cancer is one of the main diagnoses of malignancy in women in our country. Positron Emission Tomography - Computed Tomography is important because it can correctly establish the stage of the disease as well as determine recurrence, even better than diagnostic methods such as Simple Tomography or Magnetic Resonance. OBJECTIVE. To establish the main demographic aspects of the patients diagnosed with ovarian cancer that were evaluated in the Cyclotron
Positron Emission Tomography Unit of the Carlos Andrade Marín Specialty Hospital of
Quito-Ecuador. MATERIALS AND METHODS. Retrospective descriptive study. The total number of the population was 166 patients, and a sample of 103 patients with inclusion and exclusion criteria in the PET Cyclotron Unit of the Carlos Andrade Marín Specialty Hospital of the city of Quito, from 2013 to 2018, obtained from statistical bases PET Cyclotron Unit and in the database of the AS400 system of the Hospital. RESULTS Hospital. The median age of ovarian cancer patients was 56 years (IQR 48-64; minimum: 13 and maximum 85). At the time of the study, 58,3% were married
(60; 103). 43,7% (45; 103) had a child. 47,6% (49; 103) had third level studies. 64,0%
(66; 103) resided in Quito. CONCLUSION. This demographic profile highlighted the
little access of this type of diagnostic technology in patients with low educational level and in geographically remote places of Quito.
Cueva P, Yépez J. Epidemiología del cáncer en Quito 2006 - 2010). Issuu [Internet]. 2014 [citado 2019 Feb 17];15(1):182-209. ISBN-978-9942-9958-2-7 Disponible en: https://issuu.com/solcaquito/docs/epidemiologia_de_cancer_en_quito_20.
Webb PM., & Jordan, S. J. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol [Internet]. 2017 may [cited 2019 Feb 17];41:3–14. PMID: 11330452. Available from: https://www.sciencedirect.com/science/article/pii/S1521693416300918?via%3Dihub
Wong KH, Mang OWK, Au KH, Law SCK. Incidence, mortality, and survival trends of ovarian cancer in Hong Kong, 1997 to 2006: a population-based study. Hong Kong Med [Internet]. 2012 dic [cited 2019 Feb 18];18(6):466–74. PMID: 23223646. Available from: https://www.hkmj.org/abstracts/v18n6/466.htm
Zhuang Y, Wang T, Zhang G. Diffusion-Weighted Magnetic Resonance Imaging (DWI) Parameters in Benign and Malignant Ovarian Tumors with Solid and Cystic Components. J Coll Physicians Surg-Pak JCPSP [Internet]. 2019 feb [cited 2019 Feb 18];29(2):105–8. DOI: 10.29271/jcpsp.2019.02.105. Available from: https://www.jcpsp.pk/archive/2019/Feb2019/03.pdf
Wang YX, Yuan MZ, Wen ZX. Application of apparent diffusion coefficient and exponent apparent diffusion coefficient values in magnetic resonance imaging diffusion-weighted imaging to differentiate benign and malignant ovarian epithelial tumors. J Cancer Res Ther [Internet]. 2016 mar [cited 2019 Feb 18];12(1):401–5. DOI: 10.4103/0973-1482.163667. Available from: http://www.cancerjournal.net/article.asp?issn=0973-1482;year=2016;volume=12;issue=1;spage=401;epage=405;aulast=Wang
Belkić K, Belkić D. The Challenge of Ovarian Cancer: Steps Toward Early Detection Through Advanced Signal Processing in Magnetic Resonance Spectroscopy. Isr Med Assoc J IMAJ [Internet]. 2017 Aug [cited 2019 Feb 18];19(8):517–25. PMID: 28825773. Available from: https://www.ima.org.il/MedicineIMAJ/viewarticle.aspx?year=2017&month=08&page=517
Bick U, Engel C, Krug B, Heindel W, Fallenberg EM, Rhiem K, et al. High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer. Breast Cancer Res Treat [Internet]. 2019 feb 6 [cited 2019 Feb 18]. DOI: 10.1007/s10549-019-05152-9. Available from: https://link.springer.com/article/10.1007%2Fs10549-019-05152-9
Rubello D, Marzola MC, Colletti PM. The role of 18F-FDG PET/CT imaging in the diagnosis of ovarian cancer. Rev Espanola Med Nucl E Imagen Mol [Internet]. 2019 feb [cited 2019 Feb 18];38(1):50–1. DOI: 10.1016/j.remn.2018.08.003. Available from: https://www.sciencedirect.com/science/article/pii/S2253654X18301859?via%3Dihub
Khiewvan B, Torigian DA, Emamzadehfard S, Paydary K, Salavati A, Houshmand S, et al. An update on the role of PET/CT and PET/MRI in ovarian cancer. Eur J Nucl Med Mol Imaging [Internet]. 2017 jun [cited 2019 Feb 18];44(6):1079–91. DOI: 10.1007/s00259-017-3638-z. Available from: https://link.springer.com/article/10.1007/s00259-017-3638-z
Caobelli F, Alongi P, Evangelista L, Picchio M, Saladini G, Rensi M, et al. Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study. Eur J Nucl Med Mol Imaging [Internet]. 2016 mar [cited 2019 Feb 18];43(3):404–13. DOI: 10.1007/s00259-015-3184-5. Available from: https://link.springer.com/article/10.1007/s00259-015-3184-5
Nowosinska E, Avril S, Murray I, Szyszko T, Avril N. FDG-PET/CT as a molecular biomarker in ovarian cancer. Cancer Biomark Sect Dis Markers [Internet]. 2011 [cited 2019 Feb 18];8(4–5):167–75. DOI: 10.3233/CBM-2011-0219. Available from: https://content.iospress.com/openurl?genre=article&id=doi:10.3233/CBM-2011-0219
La Vecchia C. Ovarian cancer: epidemiology and risk factors. Eur J Cancer Prev Off J Eur Cancer Prev Organ ECP [Internet]. 2017 [cited 2019 Feb 18];26(1):55–62. DOI: 10.1097/CEJ.0000000000000217. Available from: https://www.ingentaconnect.com/content/wk/cej/2017/00000026/00000001/art00007
Kang SK, Reinhold C, Atri M, Benson CB, Bhosale PR, et al. ACR Appropriateness Criteria® Staging and Follow-Up of Ovarian Cancer. J Am Coll Radiol JACR [Internet]. 2018 may [cited 2019 Feb 18];15(5S):S198–207. DOI: 10.1016/j.jacr.2018.03.015. Available from: https://www.jacr.org/article/S1546-1440(18)30343-0/fulltext
USCS Data Visualizations [Internet]. Atlanta: US Cancer Statistics Data Visualization; 2016 [cited 2019 Feb 18]. Available from: https://gis.cdc.gov/Cancer/USCS/DataViz.html
Modugno F, Ness RB, Allen GO, Schildkraut JM, Davis FG, Goodman MT. Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis. Am J Obstet Gynecol [Internet]. 2004 sep [cited 2019 Feb 18];191(3):733–40. DOI: 10.1016/j.ajog.2004.03.035. Available from: https://www.ajog.org/article/S0002-9378(04)00281-9/abstract
Koushik A, Grundy A, Abrahamowicz M, Arseneau J, Gilbert L, Gotlieb WH, et al. Hormonal and reproductive factors and the risk of ovarian cancer. Cancer Causes Control CCC [Internet]. 2017 may [cited 2019 Feb 18];28(5):393–403. DOI: 10.1007/s10552-016-0848-9. Available from: https://link.springer.com/article/10.1007%2Fs10552-016-0848-9
Merritt MA, De Pari M, Vitonis AF, Titus LJ, Cramer DW, Terry KL. Reproductive characteristics in relation to ovarian cancer risk by histologic pathways. Hum Reprod Oxf Engl [Internet]. 2013 may[cited 2019 Feb 18];28(5):1406–17. DOI: 10.1093/humrep/des466. Available from: https://academic.oup.com/humrep/article/28/5/1406/938981
La Vecchia C. Epidemiology of ovarian cancer: a summary review. Eur J Cancer Prev Off J Eur Cancer Prev Organ ECP [Internet]. 2001 apr [cited 2019 Feb 18];10(2):125–9. PMID: 11330452. Available from: https://insights.ovid.com/pubmed?pmid=11330452
Dos Santos Silva I, Swerdlow AJ. Recent trends in incidence of and mortality from breast, ovarian and endometrial cancers in England and Wales and their relation to changing fertility and oral contraceptive use. Br J Cancer [Internet].1995 aug [cited 2019 Feb 18];72(2):485–92. PMID: 7640237. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033995/
Rivas LM, González M, Hernández RJ. Perfil epidemiológico del cáncer de ovario. Ginecol Obstet México [Internet]. 2011[cited 2019 Feb 18];79(09):562–8. ISSN-0300-9041. Available from: https://www.medigraphic.com/pdfs/ginobsmex/gom-2011/gom119g.pdf
The authors who publish in this journal accept the following conditions:
1. The authors retain the copyright and grant to the CAMbios MEDICAL-SCIENTIFIC JOURNAL HECAM the right of the first publication, with the work registered with the Creative Commons attribution license, which allows third parties to use the published material provided that they mention the authorship of the work and the first publication in this journal.
2. Authors can make other independent and additional contractual agreements for the non-exclusive distribution of the version of the article published in this journal (for example, include it in an institutional repository or publish it in a book) as long as it clearly indicates that the work was published. for the first time in the CAMbios MEDICAL-SCIENTIFIC JOURNAL HECAM.
